PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
 
J Psychiatry Neurosci. 2000 May; 25(3): 255–261.
PMCID: PMC1407715

Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Abstract

OBJECTIVE: To establish specific criteria by which selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome may be identified. DATA SOURCES: MEDLINE and PSYCHLIT databases were searched for case reports published from 1986 to 1997 inclusive, and references of relevant articles were also searched. STUDY SELECTION: Forty-six case reports of symptoms following the discontinuation of fluoxetine, fluvoxamine, paroxetine or sertraline were selected. Three studies of SSRI discontinuation were also reviewed. DATA EXTRACTION: Demographic and treatment information, as well as the timing, duration, number, nature and frequency of dicontinuation symptoms. DATA SYNTHESIS: Paroxetine was most frequently implicated. The drug had been tapered in half of the cases. In some cases, symptom onset began during taper, whereas, in most cases, symptoms began within 1 to 3 days of drug discontinuation. Fifty-three different symptoms were reported, with dizziness being the most common. Other common symptoms were nausea or emesis, fatigue, headache, gait instability and insomnia. Shock-like sensations, paresthesia and visual disturbances were the most rare. Without intervention, symptoms persisted for more than a week in half of the cases. In cases in which the SSRI was restarted, symptoms resolved within 72 hours. In some cases, withdrawal symptoms recurred when the same SSRI was again discontinued. CONCLUSIONS: Findings were used to construct diagnostic criteria for the SSRI discontinuation syndrome. These criteria are 2 or more of the following symptoms developing within 1 to 7 days of discontinuation or reduction in dosage of an SSRI after at least 1 month's use, when these symptoms cause clinically significant distress or impairment and are not due to a general medical condition or recurrence of a mental disorder: dizziness, light-headedness, vertigo or feeling faint; shock-like sensations or paresthesia; anxiety; diarrhea; fatigue; gait instability; headache; insomnia; irritability; nausea or emesis; tremor; and visual disturbances.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997 Jul;58(7):291–297. [PubMed]
  • Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997;58 (Suppl 7):5–10. [PubMed]
  • Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 1997;58 (Suppl 7):17–22. [PubMed]
  • Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry. 1997;58 (Suppl 7):23–27. [PubMed]
  • Amsden GW, Georgian F. Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy. 1996 Jul-Aug;16(4):684–686. [PubMed]
  • Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994 Feb;151(2):289–289. [PubMed]
  • Berlin CS. Fluoxetine withdrawal symptoms. J Clin Psychiatry. 1996 Feb;57(2):93–94. [PubMed]
  • Bloch M, Stager SV, Braun AR, Rubinow DR. Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet. 1995 Jul 1;346(8966):57–57. [PubMed]
  • Cooper GL. The safety of fluoxetine--an update. Br J Psychiatry Suppl. 1988 Sep;(3):77–86. [PubMed]
  • Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry. 1995 Aug;152(8):1235–1234. [PubMed]
  • Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy. 1995 Nov-Dec;15(6):778–780. [PubMed]
  • Einbinder E. Fluoxetine withdrawal? Am J Psychiatry. 1995 Aug;152(8):1235–1235. [PubMed]
  • Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol. 1995 Oct;15(5):374–375. [PubMed]
  • Frost L, Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995 May;152(5):810–810. [PubMed]
  • Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol. 1994 Jun;14(3):206–207. [PubMed]
  • Leiter FL, Nierenberg AA, Sanders KM, Stern TA. Discontinuation reactions following sertraline. Biol Psychiatry. 1995 Nov 15;38(10):694–695. [PubMed]
  • Louie AK, Lannon RA, Ajari LJ. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry. 1994 Mar;151(3):450–451. [PubMed]
  • Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? Biol Psychiatry. 1993 Jun 1;33(11-12):851–852. [PubMed]
  • Pacheco L, Malo P, Aragues E, Etxebeste M. More cases of paroxetine withdrawal syndrome. Br J Psychiatry. 1996 Sep;169(3):384–384. [PubMed]
  • Phillips SD. A possible paroxetine withdrawal syndrome. Am J Psychiatry. 1995 Apr;152(4):645–646. [PubMed]
  • Pyke RE. Paroxetine withdrawal syndrome. Am J Psychiatry. 1995 Jan;152(1):149–150. [PubMed]
  • Reeves RR, Pinkofsky HB. Lhermitte's sign in paroxetine withdrawal. J Clin Psychopharmacol. 1996 Oct;16(5):411–412. [PubMed]
  • Rosenstock HA. Sertraline withdrawal in two brothers: a case report. Int Clin Psychopharmacol. 1996 Mar;11(1):58–59. [PubMed]
  • Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry. 1991 Sep;148(9):1263–1263. [PubMed]
  • Szabadi E. Fluvoxamine withdrawal syndrome. Br J Psychiatry. 1992 Feb;160:283–284. [PubMed]
  • Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995 Sep;167(3):374–379. [PubMed]
  • Arya DK. Withdrawal after discontinuation of paroxetine. Aust N Z J Psychiatry. 1996 Oct;30(5):702–702. [PubMed]
  • Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry. 1993 Apr;54(4):146–149. [PubMed]
  • Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996 Oct;16(5):356–362. [PubMed]
  • Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996 Dec;42(6):757–763. [PubMed]
  • Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry. 1997;58 (Suppl 10):63–72. [PubMed]
  • Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry. 1980 Nov;137(11):1395–1398. [PubMed]
  • Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995 Mar;52(3):173–188. [PubMed]
  • Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry. 1996;57 (Suppl 2):24–30. [PubMed]
  • Dilsaver SC. Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(2):137–161. [PubMed]
  • Dilsaver SC. Antidepressant withdrawal syndromes: phenomenology and pathophysiology. Acta Psychiatr Scand. 1989 Feb;79(2):113–117. [PubMed]
  • Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry. 1984 Feb;19(2):237–256. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association